15-Year gene therapy study aims to slow vision loss in rare genetic disorder
NCT ID NCT02065011
Summary
This study is following 9 patients for up to 15 years to check the long-term safety of an experimental gene therapy called SAR421869. The therapy was given as a single injection into the eye in a previous study, and researchers now want to see if it continues to be safe and if it can slow down the vision loss caused by Usher syndrome type 1B. The study is not recruiting new participants; it is only monitoring those who received the treatment earlier.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for USHER'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 250001
Paris, 75012, France
-
Oregon Health and Science University Site Number : 840001
Portland, Oregon, 97239-3098, United States
Conditions
Explore the condition pages connected to this study.